A
Alison Matsunaga
Researcher at Children's Hospital Oakland Research Institute
Publications - 2
Citations - 1800
Alison Matsunaga is an academic researcher from Children's Hospital Oakland Research Institute. The author has contributed to research in topics: Antibody & Virus. The author has an hindex of 2, co-authored 2 publications receiving 1584 citations.
Papers
More filters
Journal ArticleDOI
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J. Manco-Johnson,Marilyn J. Manco-Johnson,Thomas C. Abshire,Amy D. Shapiro,Brenda Riske,Michele R. Hacker,Ray F. Kilcoyne,J. David Ingram,M L Manco-Johnson,Sharon Funk,Linda J. Jacobson,Leonard A. Valentino,W. Keith Hoots,George R. Buchanan,Donna DiMichele,Michael Recht,Deborah L Brown,Cindy A. Leissinger,Shirley Bleak,Alan R. Cohen,Prasad Mathew,Alison Matsunaga,Desiree Medeiros,Diane J. Nugent,Gregory Thomas,Alexis A. Thompson,Kevin McRedmond,J. Michael Soucie,Harlan Austin,Bruce L. Evatt +29 more
TL;DR: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A.
Journal ArticleDOI
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
Chengwen Li,Nattee Narkbunnam,Nattee Narkbunnam,Richard Jude Samulski,Aravind Asokan,Genlin Hu,L. J. Jacobson,M. J. Manco-Johnson,Paul E. Monahan,Marilyn J. Manco-Johnson,Brenda Riske,Ray F. Kilcoyne,M L Manco-Johnson,Sharon Funk,Linda J. Jacobson,J. David Ingram,Thomas C. Abshire,Thomas C. Abshire,Amy D. Shapiro,Michele R. Hacker,Leonard A. Valentino,W. Keith Hoots,Deborah L Brown,George R. Buchanan,Donna DiMichele,Michael Recht,Cindy A. Leissinger,Shirley Bleak,Alan R. Cohen,Prasad Mathew,Alison Matsunaga,Desiree Medeiros,Diane J. Nugent,Gregory Thomas,Alexis A. Thompson,Kevin McRedmond,J. Michael Soucie,Harlan Austin,Bruce L. Evatt +38 more
TL;DR: The results may guide rational design of clinical trials using alternative AAV serotypes and suggest that younger patients who are given AAV gene therapy will benefit from the lower prevalence of NAbs.